Zn-c3-005: A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer

Zn-c3-005: A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer
Enrolling By Invitation
100 years or below
Female
Phase 2

Brief description of study

A Phase 2 study to evaluate the clinical activity, safety, and potentially predictive biomarker profile of ZN-c3 in subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Detailed description of study

This study is Enrolling by Invitation at Lancaster General Hospital - ABBCI

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: In clinic, in person
  • Age: 100 years or below
  • Gender: Female

Inclusion Criteria:
  • Age 18 years or older
  • High-grade serous ovarian cancer
  • Prior therapy: Subjects must have platinum-resistant disease, one to 4 prior lines or regimens are allowed (1 to 5 prior lines are permitted in part 1b), and prior bevacizumab treatment is required
  • Measurable disease per RECIST Version 1.1.
  • Adequate hematologic and organ function
Exclusion Criteria:
  • Any of the following treatment interventions within the specified time frame prior to C1D1: major surgery within 28 days, any chemotherapy or targeted tumor therapy within 14 days or 5 half-lives (whichever is shorter);, Radiation therapy within 21 days, Autologous or allogeneic stem cell transplant within 3 months, Current use of any other investigational drug therapy <28 days or 5 half-lives (whichever is shorter)
  • Prior therapy with Zn-c3 or any other WEE1 inhibitor, ATR inhibitor, or CHK1/2 inhibitor
  • A serious illness or medical condition(s) including, but not limited to: Any evidence of bowel obstruction as determined by air/fluid levels on computed technology (CT) scan, recent hospitalization for bowel obstruction within 3 months prior to C1 D1, or recurrent paracentesis or thoracentesis within 6 weeks prior to C1 D1

Updated on 01 Aug 2024. Study ID: ZN-c3-005
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research